Don't let AbbVie fool FTC with an easy divestiture, plead critics in latest attack on $63B Allergan buyout
If the FTC must let AbbVie and Allergan go ahead with their merger, at least make them divest their latest blockbuster on the market, a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
